

Program

10:00 a.m.

Opening

Cecília Rodrigues (Vice-Rector ULisboa) Mónica Oliveira (Coordinator redeSAÚDE) Luís Costa and João Sanches (Workshop Chairs)

Morning Sessions' Chairs

Luís Costa (FM ULisboa) and João Sanches (IST ULisboa)

10:15 a.m.

Defining genetic risk for cancer

Chairs: Luís Costa (FM ULisboa) and João Sanches (IST ULisboa)

- Strategic options in the real world: Mainstreaming Inês Sasso Pinho / Rita Sousa (ULS Santa Maria, FM ULisboa)
- EVITA platform Tamara Milagre (EVITA)
- BRIGHT study: Polygenic risk for breast cancer Gonçalo Costa (FM ULisboa, ULS Santa Maria)
- Discussion

11:00 a.m.

Academic studies

- I. MCPP academic study
 - Marta Martins (iMM-JoãoLobo Antunes)
- 2. FRONTAL study: Application of a genomic panel to the Portuguese
 - Sara Dâmaso (FM ULisboa, ULS Santa Maria)
- 3. Discussion

12:15 a.m.

Lunch break















Afternoon Sessions' Chairs João Sanches (IST ULisboa) and Peter Jordan (FC ULisboa and INSA) I:45 p.m. Genomics as guidance for treatment options Chairs: João Sanches (IST ULisboa) and Peter Jordan (FC ULisboa and INSA) I. Lung cancer and cholangiocarcinoma as models Teresa Pacheco (FM ULisboa) 2. Identifying patients for clinical trials André Mansinho (START Lisbon, FM ULisboa) 3. Discussion The role of genomics in defining recurrence risk in Oncology I. Colorectal cancer: ctDNA and selection of patients for adjuvant chemotherapy Karen Lin (Natera) 2. Breast cancer: When the genomic platform makes a difference Ana Teresa Padrão (Hospital da Luz) 3. Discussion 3:35 p.m. Artificial Intelligence I. Beyond genomics Emanuel Gonçalves (IST ULisboa) 2. Discussion 4:00 p.m. Final remarks João Sanches (IST ULisboa) and Luís Costa (FM ULisboa)		
Chairs: João Sanches (IST ULisboa) and Peter Jordan (FC ULisboa and INSA) 1. Lung cancer and cholangiocarcinoma as models Teresa Pacheco (FM ULisboa) 2. Identifying patients for clinical trials André Mansinho (START Lisbon, FM ULisboa) 3. Discussion 2:45 p.m. The role of genomics in defining recurrence risk in Oncology 1. Colorectal cancer: ctDNA and selection of patients for adjuvant chemotherapy Karen Lin (Natera) 2. Breast cancer: When the genomic platform makes a difference Ana Teresa Padrão (Hospital da Luz) 3. Discussion 3:35 p.m. Artificial Intelligence 1. Beyond genomics Emanuel Gonçalves (IST ULisboa) 2. Discussion Final remarks		
1. Lung cancer and cholangiocarcinoma as models Teresa Pacheco (FM ULisboa) 2. Identifying patients for clinical trials André Mansinho (START Lisbon, FM ULisboa) 3. Discussion 2:45 p.m. The role of genomics in defining recurrence risk in Oncology 1. Colorectal cancer: ctDNA and selection of patients for adjuvant chemotherapy Karen Lin (Natera) 2. Breast cancer: When the genomic platform makes a difference Ana Teresa Padrão (Hospital da Luz) 3. Discussion 3:35 p.m. Artificial Intelligence 1. Beyond genomics Emanuel Gonçalves (IST ULisboa) 2. Discussion 4:00 p.m. Final remarks	1:45 p.m.	Genomics as guidance for treatment options
Teresa Pacheco (FM ULisboa) 2. Identifying patients for clinical trials		Chairs: João Sanches (IST ULisboa) and Peter Jordan (FC ULisboa and INSA)
André Mansinho (START Lisbon, FM ULisboa) 3. Discussion 2:45 p.m. The role of genomics in defining recurrence risk in Oncology 1. Colorectal cancer: ctDNA and selection of patients for adjuvant chemotherapy Karen Lin (Natera) 2. Breast cancer: When the genomic platform makes a difference Ana Teresa Padrão (Hospital da Luz) 3. Discussion 3:35 p.m. Artificial Intelligence 1. Beyond genomics Emanuel Gonçalves (IST ULisboa) 2. Discussion 4:00 p.m. Final remarks		Teresa Pacheco (FM ULisboa)
1. Colorectal cancer: ctDNA and selection of patients for adjuvant chemotherapy Karen Lin (Natera) 2. Breast cancer: When the genomic platform makes a difference Ana Teresa Padrão (Hospital da Luz) 3. Discussion 3:35 p.m. Artificial Intelligence 1. Beyond genomics Emanuel Gonçalves (IST ULisboa) 2. Discussion 4:00 p.m. Final remarks		André Mansinho (START Lisbon, FM ULisboa)
chemotherapy Karen Lin (Natera) 2. Breast cancer: When the genomic platform makes a difference Ana Teresa Padrão (Hospital da Luz) 3. Discussion 3:35 p.m. Artificial Intelligence 1. Beyond genomics Emanuel Gonçalves (IST ULisboa) 2. Discussion 4:00 p.m. Final remarks	2:45 p.m.	The role of genomics in defining recurrence risk in Oncology
I. Beyond genomics Emanuel Gonçalves (IST ULisboa) 2. Discussion 4:00 p.m. Final remarks		 chemotherapy Karen Lin (Natera) Breast cancer: When the genomic platform makes a difference Ana Teresa Padrão (Hospital da Luz)
Emanuel Gonçalves (IST ULisboa) 2. Discussion 4:00 p.m. Final remarks	3:35 p.m.	Artificial Intelligence
		Emanuel Gonçalves (IST ULisboa)
João Sanches (IST ULisboa) and Luís Costa (FM ULisboa)	4:00 p.m.	Final remarks
		João Sanches (IST ULisboa) and Luís Costa (FM ULisboa)













